PSORIASIS Is ustekinumab superior to etanercept for psoriasis?

被引：6
|
作者：
Kuhn, Annegret [1 ]
Luger, Thomas A. [1 ]
机构：
[1] Univ Munster, Dept Dermatol, D-48149 Munster, Germany
来源：
NATURE REVIEWS RHEUMATOLOGY | 2010年 / 6卷 / 09期
关键词：
INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; TNF INHIBITION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1038/nrrheum.2010.134
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe psoriasis found that ustekinumab was superior to high-dose etanercept over a 12-week period; however, several questions remain to be addressed.
引用
收藏
页码：500 / 501
页数：3
相关论文
共 50 条
  • [11] Weight and demographic characteristics of psoriasis patients treated with adalimumab, etanercept, or ustekinumab
    Meyer, Roxanne
    Yeaw, Jason
    Zhang, Mingliang
    Hines, Dionne
    Wade, Ron
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB257 - AB257
  • [12] Etanercept in psoriasis
    Papp, KA
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (10) : 2139 - 2146
  • [13] Pustular psoriasis, palmoplantar psoriasis, erythodermal psoriasis and etanercept
    Lopez-Estebaranz, J. L.
    Ruiz-Genao, D.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 35 - 39
  • [14] Etanercept in juvenile psoriasis [Etanercept in dertherapie der juvenilen psoriasis]
    Beikert F.C.
    Augustin M.
    Radtke M.A.
    Der Hautarzt, 2012, 63 (5): : 406 - 410
  • [15] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Villacorta, Reginald
    Hay, Joel W.
    Messali, Andrew
    PHARMACOECONOMICS, 2013, 31 (09) : 823 - 839
  • [16] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Reginald Villacorta
    Joel W. Hay
    Andrew Messali
    PharmacoEconomics, 2013, 31 : 823 - 839
  • [17] Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis
    Martin, Silas
    Feldman, Steven R.
    Augustin, Matthias
    Szapary, Philippe
    Schenkel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (03) : 138 - 143
  • [18] Comparative Treatment Patterns Among Psoriasis Patients Using Adalimumab, Etanercept, or Ustekinumab
    Carter, Chureen
    Wilson, Kathleen L.
    Smith, David
    Lee, Seina
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2016, 8 (05) : 191 - 198
  • [19] The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients
    Young, Melodie S.
    Horn, Elizabeth J.
    Cather, Jennifer C.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (01) : 9 - 13
  • [20] Systemic profile of psoriasis: the effects of ustekinumab and etanercept following 12 weeks of treatment
    Brodmerkel, C.
    Kikuchi, T.
    Fidelus-Gort, R.
    Khatcherian, A.
    Novitskaya, I
    Baribaud, F.
    Krueger, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S26 - S26
12345